Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.
Regorafenib|Raltitrexed|Colorectal Neoplasms|Third-line Treatment
DRUG: Regorafenib|DRUG: Raltitrexed
Progression-free Survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first., one year
Objective Response Rate (ORR), ORR, determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment., one year|Disease Control Rate (DCR), Determined using RECIST v1.1 criteria., one year|Overall Survival (OS), Duration from the date of initial treatment to the date of death due to any cause., two years|Incidence and severity of adverse events (AE) and serious adverse events (SAE), Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0., two years
This is a multicenter, open, single-arm, phase I/II study to evaluate the efficacy and safety of regorafenib plus raltitrexed as third-line treatment in patients with advanced colorectal cancer.This Phase Ib/II study consists of two parts, Phase Ib, an open-ended, single-arm, multi-centre, dose-escalation study evaluating regorafenib, and Phase II, an open-label, multi-centre study evaluating the efficacy and safety of regorafenib in combination with raltitrexed.The primary study endpoint: progression-free survival (PFS).The secondary end endpoints include ORR (overall effectiveness of tumour treatment)，DCR (disease control rate)，3 month/6 month/9 month/12 month survival OS%，OS (overall survival)，incidence and severity of adverse events (AEs), serious adverse events (SAEs).